UNSPSC 51386012: Metamfazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H11N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Q0YU79408, chemically known as 3(2h)-pyridazinon, 4-amino-6-methyl-2-phenyl- but generally known as metamfazone, which bears US NIH Compound Identifier 176887. European Medicines Agency schedules Metamfazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08807MIG.

UNSPSC 51386012 Metamfazone, a Commodity code, encompasses pharmaceutical products and drug-related systems procured by state and local health agencies, though recent solicitations under this code show broader pharmaceutical procurement activity including naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter products rather than metamfazone specifically. State and local governments use this code to purchase pharmaceutical inventory for public health initiatives, emergency response programs, and health benefit administration across county health departments, state health agencies, and multistate cooperative purchasing alliances. Issuing bodies include county health systems (Seminole County, Florida), state health commissions (Texas Health and Human Services Commission), and cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance) serving multiple jurisdictions including state and local facilities.

Recent procurement activity spans Florida, Texas, Minnesota, and Oregon through multiple solicitation types. Seminole County, Florida released an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program focused on direct contracting between the state pharmacy benefit program and manufacturers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) across participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026 and performance penalties ranging from $200 to $1,500 per violation.